Jeremy Skillington of Poolbeg Pharma: licence acquired to use innovative oral delivery technology to address large, fast-growing opportunity

Dec 14, 2022

If you find this podcast useful please give it a rating and review on iTunes by clicking here

POOLBEG PHARMA POLB

Jeremy Skillington CEO of Poolbeg Pharma discusses the acquisition of an exclusive licence from to use innovative oral delivery technologies in metabolic syndrome related diseases including obesity, pre-diabetes and diabetes. Obesity alone costs the US healthcare system c. $173bn a year.

Highlights

Following the licence, in H1 2023 Poolbeg will rapidly commence a proof-of-technology clinical trial to determine that a Glucagon-like Peptide 1 receptor (GLP-1) agonist can be safely delivered orally in humans. GLP-1 agonists, which are used to treat diabetes and obesity, represent an extremely large, fast-growing opportunity estimated to grow to c.$22bn per annum by 2025. At present, all but one GLP-1 products are injectables, which are more onerous for patients than oral delivery.

To read the entire RNS click here

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Market Sectors

Asiamet sells KSK copper project for US$105 million cash

Georgina Energy secures equity and debt funding from new institutional investor

The real reason the gold price is so high, and who will be the winners and losers

Mindflair welcomes Sure Valley Ventures’ investment in hybrid AI company

Amazing AI makes initial digital asset treasury purchase

Hybridan Small Cap Feast: 05 November 2025

Restore: Research

Diales Group: Research

Ultimate Products: Research

IG Design Group: Research

Mining Matters: Manganese in Botswana with Charlie Fitzroy of Giyani Metals

Operating in Nevada: Great Western Mining

Mining Matters: Anthony Viljoen, the CEO of Andrada Mining

Cailey Barker: Specialty metals, gold, and the state of the mining sector

Mining Matters: SP Angel’s John Meyer on Commodities, Capital, and Change

Jeremy Skillington of Poolbeg Pharma: licence acquired to use innovative oral delivery technology to address large, fast-growing opportunity

Jeremy Skillington CEO of Poolbeg Pharma discusses the acquisition of an exclusive licence from to use innovative oral delivery technologies in metabolic syndrome related diseases including obesity, pre-diabetes and diabetes. Obesity alone costs the US healthcare system c. $173bn a year.